Antisoma drops mid-stage anticancer antibody
This article was originally published in Scrip
Executive Summary
Antisoma has discontinued a Phase II trial of AS1402, an anticancer antibody, in breast cancer after early data showed that the drug was unlikely to yield positive efficacy effects. The company has no plans for future studies of the drug.